



1

REGISTER FOR CEs



Click link below or scan QR code

<https://www.lecturepanda.com/r/2026NCODAFallSummit>

After registering, you will receive a confirmation email from lecturepanda with a unique link. **Please do not share this link, it is unique to your profile.**

2

COMPLETE THE PRE-ASSESSMENT



Please complete the pre-assessment quiz for each CE activity before the session begins.

Pre-assessments close 15 minutes after each CE session begins.

3

OBTAINING CE CREDIT

Complete all LecturePanda credit requirements within 60 days, by:

DEC

29

Pharmacists; Pharmacy Technicians:

- ACPE credit transmitted electronically

Physicians; Nurses; Nurse

Practitioners; Physician Assistants:

- Refer to the PACE handout

2026 NCODA Fall Summit

Physician, Nurse, Nurse Practitioner, Physician Assistant Sessions

CE Information

October 28 - 30, 2026 | Orlando, FL

Provided by Partners for Advancing Clinical Education and NCODA

Target Audience

This conference is intended for oncology healthcare providers that include; pharmacists, pharmacy technicians, physicians, physician assistants, nurses, and nurse practitioners who care for patients within oncology

Session Educational Objectives

Upon completion of this session, participants should be able to:

Future of ADCs: Preparing Practices for What's Coming

0.75 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

This educational activity is supported by an independent medical education grant from GSK.

- Describe current approved indications and the expansion of antibody–drug conjugates (ADCs) into earlier lines of therapy and evolving combination regimens.
- Explain how novel payloads, emerging biomarkers, bispecific ADCs, and combinations of ADCs with bispecific antibodies may influence patient selection and treatment sequencing.
- Identify operational implications of evolving ADC therapies for oncology practices, including biomarker testing, agent-specific toxicity monitoring, patient counseling, and interprofessional care coordination.

Navigating the Evolving Multiple Myeloma Treatment Landscape: Bispecifics, CAR-T, & CELMoDs

1.0 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Review the evolving role of CAR T-cell therapy, bispecific antibodies, and CELMoDs in the management of relapsed/refractory multiple myeloma, including considerations for treatment selection and sequencing.
- Describe evidence-based strategies for recognizing, grading, and managing treatment-related toxicities associated with CAR T-cell therapy and bispecific antibodies, including cytokine release syndrome (CRS), neurotoxicity (ICANS), and infection risk.
- Discuss operational and workflow considerations for implementing bispecific antibody therapy in community oncology practice, including step-up dosing, patient monitoring, interdisciplinary communication, and coordination of care.
- Identify the roles of oncology multidisciplinary team in supporting safe medication-use processes, treatment coordination, and patient education for emerging multiple myeloma therapies.
- Outline practical approaches to optimizing patient outcomes through multidisciplinary management of patients receiving CAR T-cell therapy, bispecific antibodies, and novel CELMoD therapies.

1:45-2:45 pm Breakout Sessions (concurrent)

1.0 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

Advancing Care in Low-Grade Serous Ovarian Cancer: Integrating Molecular Testing into Clinical Decision Making

This educational activity is supported by an independent medical education grant from Verastem, Inc.

- Describe the molecular and biological characteristics of low-grade serous ovarian cancer (LGSOC), including key differences from other ovarian cancer subtypes.
- Identify recommended molecular testing approaches in ovarian cancer, including biomarkers relevant to LGSOC.
- Discuss current and emerging treatment strategies for patients with LGSOC based on molecular and clinical factors.
- Interpret molecular testing results from patient-case examples to guide treatment selection and clinical decision-making in LGSOC.

From Prescription to Persistence: Optimizing Access & Adherence Across the OAM Journey

- Describe how the NCODA/ONS Oral Anticancer Medication (OAM) Care Compass may be used to address barriers to cancer care
- Examine the role of workflow ownership in a formal OAM program to reduce gaps in care.
- Compare approaches used by formal versus informal OAM programs to address barriers across the patient journey.
- Demonstrate application of available resources to address workflow gaps within individual practice settings through group activity.

2:45-3:45 pm Breakout Sessions (concurrent)

1.0 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

Fixed Duration, Forward Thinking: Evolving CLL Treatment

- Discuss the key clinical evidence, safety profiles, and practical considerations associated with fixed-duration treatment approaches in chronic lymphocytic leukemia
- Apply patient- and disease-specific factors that influence the selection of fixed-duration therapy in CLL through case-based examples.
- Identify patient-specific factors that warrant pharmacist review when supporting fixed-duration therapy in CLL through case-based examples.

Protecting Future Possibilities: Integrating Fertility Preservation Across the Cancer Care Continuum

- Discuss treatment-related infertility risks, fertility preservation options, and reproductive health considerations for pediatric, adolescent and young adult, and adult patients within multidisciplinary oncology care.
- Apply patient-centered communication and shared decision-making strategies regarding fertility preservation in patient case scenarios across the cancer care continuum.

Thinking Beyond the Task: Strengthening Clinical Judgment & Accountability in Oncology Nursing

- Describe how Tanner's Clinical Judgment Model (noticing, interpreting, responding, reflecting) applies to evolving clinical concerns, including infusion-related reactions (IRR) and triage/telephone symptom management in a variety of oncology settings.
- Discuss how culture of safety, near-miss/miss reporting, and systems-level factors support or constrain clinical judgment at the point of care.
- Explain how clinicians across Benner's novice-to-expert continuum contribute differently, with advanced beginners bringing transferable safety knowledge from prior settings to inform systems and protocols, and experts bringing pattern recognition to the bedside.
- Outline how principles of accountability and emotional intelligence inform an appropriate clinical response in a case-based infusion scenario.

The New Access Landscape: Preparing Oncology Practices for Coverage Changes in 2027

- Describe the pending enrollment criteria and barriers to enrollment in Medicaid as well as the Marketplace set in place by the One Big Beautiful Bill Act (OBBBA) and the Marketplace Integrity and Affordability Final Rule.
- Discuss how the new enrollment criteria and barriers for Medicaid as well as the Marketplace may impact insurance coverage, treatment access, and financial burden for patients with chronic medical conditions.

- Identify preparation strategies for oncology care teams for the potential impact of these policy changes on their patient populations.

From Implementation to Impact: Lessons from the NCODA BTCE Mentorship Program

1.0 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

This educational activity is supported by an independent medical education grant from Pfizer.

- Describe the roles, workflows, and resources needed to support bispecific T-cell engager (BTCE) therapy implementation in oncology practice.
- Explain approaches for addressing staff training, toxicity management, REMS processes, care coordination, and transitions of care during BTCE therapy implementation.
- Discuss strategies to combat barriers to BTCE therapy implementation in oncology practice.

Poster Presentations

1.0 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

AI Unfiltered: A Live PQI Podcast on the Future of Oncology

0.75 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Define foundational AI concepts including machine learning, generative AI, and large language models.
- Describe key benefits, limitations, and safety considerations associated with the use of AI in healthcare and oncology.
- Identify current and emerging applications of AI in routine oncology care, including diagnosis and patient education and communication.

The Power of the Particle: Radioligands Transforming Cancer Care

0.75 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Describe the basic principles of particulate and non-particulate radiation in how it pertains to cellular toxicity and death.
- Identify when a medication may interfere with the appropriate use of a diagnostic or therapeutic radiopharmaceutical in the detection and treatment of disease.
- Recognize the basic concept of theranostics and its emerging relevance in the oncology space.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Faculty/Planning Committee Member	Relevant Financial Relationship(s)
Scott Freeswick (planning committee)	Advisory Board: Merck, J&J/Janssen, Genmab, Pharmacosmos, Amneal, AVYXA
Astrid Slaughter, PharmD, PhD, BCOP, BCSCP	Speaker: BeOne, Regeneron; Advisory Board: Celcuity
Jad Chahoud, MD, MPH-MHA	Advisory Board/Consulting: Merck, Pfizer, Exelixis, Aveo, Eisai, and Mycaregorythm
Andrew Cowan, MD	Consultant/Principal Investigator: J&J, Regeneron, Sanofi; Independent Contractor/Consultant/Principal

	Investigator: BMS; Independent Contractor: HopeAI, Consultant: Kite/Arcellx
Elizabeth Rauschenberg, MSN, APRN, FNP-C	Speaker: McKesson
Attaya Suvannasankha, MD	Advisory Board/Principal Investigator: Janssen Oncology, Regeneron, Pfizer; Advisory Board/Principal Investigator/Independent Contractor: BMS; Principal Investigator: C4 Therapeutics; Independent Contractor: Karyopharm
Megan May, PharmD, BCOP, FHOPA, FAPO	Advisory Board/Consultant/Speaker: Amgen, DSI, GSK, Pharmacosmos, Abbie, Genmab
Kelly Brunk, PharmD, MBA, BCOP, NCODA	Speaker: Pfizer
Brooke Adams, PharmD, BCOP	Consultant/Speaker: Amgen, Pfizer, Incyte, GSK, Genmab/Abbie, J&J, Regeneron, Omeros
David Patel, PharmD, BCOP	Advisory Board: Sanofi, Syndax
Vince Sung, PharmD, MBA, BCOP, BCSCP	Advisory Board: Incyte, Urogen, Amgen; Speaker: Janssen
Chadi Nabhan, MD, MBA, FACP	Stockholder: Ryght AI
Nicolo Mastascusa, PharmD, BCNP	Consultant: Novartis
Noor Naffakh	Other: Pfizer; Speaker: Binaytara
Lauren Yarbro	Consultant: Integra Connect; Speaker: MJH Life Sciences
Brooke Looney	Advisory Board: AZ, J&J; Principal Investigator: Takeda
Chelsea Renfro	Principal Investigator: UCB
Manale Maksour	Advisory Board: Pharmacosmos, Gilead
Brooke Peters	Consultant/Speaker: Amgen, Janssen, Regeneron, Pfizer; Advisory Board: Genentech, Regeneron

All other **faculty, planning committee members** and **planners** have no relevant financial relationships.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and NCODA. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this live activity for a maximum of 7.25 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Medical Education



Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 7.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 7.25 contact hours.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Instructions for Credit

CE Credit for the 2026 NCODA Fall Summit can be claimed through the LecturePanda platform. To register, please visit: <https://www.lecturepanda.com/r/2026NCODAFallSummit>

Compounding Under the Microscope: Investigating Contamination, Quality, & Safety in Oncology Practice

CE Accreditation: Pharmacists, Pharmacy Technicians

Date of Activity: October 28, 2026

LecturePanda Exp Date: December 27, 2026

SESSION DESCRIPTION

This interactive, station-based workshop will engage oncology pharmacy professionals in applying quality and safety principles to hazardous sterile compounding. Through live demonstrations, guided activities, and case-based problem solving, participants will explore hazardous drug preparation, cleaning and decontamination, hazardous drug residue control, and environmental monitoring. Participants will identify potential contamination and occupational exposure risks and analyze environmental monitoring findings to determine appropriate follow-up actions. Designed for varying levels of sterile compounding experience, the activity will reinforce foundational concepts while challenging experienced practitioners to identify opportunities to strengthen quality, safety, and adherence to USP <797> and <800> requirements in oncology practice.

LEARNING OBJECTIVES:

1. Describe hazardous sterile compounding practices that support preparation quality and personnel safety.
2. Explain the role of cleaning, decontamination, and hazardous drug residue control in reducing contamination and occupational exposure.
3. Analyze cases involving unexpected or failed environmental monitoring results, potential contributing factors, and appropriate follow-up actions.

Navigating the Evolving Multiple Myeloma Treatment Landscape: Bispecifics, CAR-T, & CELMoDs

CE Accreditation: Pharmacists, Pharmacy Technicians, Physicians, Nurses, Nurse Practitioners, Physician Assistants

Date of Activity: October 29, 2026

LecturePanda Exp Date: December 28, 2026

SESSION DESCRIPTION

This activity will review the evolving role of CAR T-cell therapy, bispecific antibodies, and cereblon E3 ligase modulatory drugs (CELMoDs) in multiple myeloma, including their movement into earlier lines of treatment. Through multidisciplinary expert discussion, participants will explore treatment selection and sequencing, recognition and management of treatment-related toxicities, and supportive care considerations. The session will also address operational and workflow considerations for delivering these therapies in community oncology practice. Participants will examine how multidisciplinary team members support safe medication use, patient education, and coordination of care across community and academic settings.

LEARNING OBJECTIVES

1. Review the evolving role of CAR T-cell therapy, bispecific antibodies, and Cereblon E3 Ligase Modulatory Drugs (CELMoDs) in the management of relapsed/refractory multiple myeloma, including considerations for treatment selection and sequencing.
2. Describe evidence-based strategies for recognizing, grading, and managing treatment-related toxicities associated with CAR T-cell therapy and bispecific antibodies, including cytokine release syndrome (CRS), neurotoxicity (ICANS), and infection risk.
3. Discuss operational and workflow considerations for implementing bispecific antibody therapy in community oncology practice, including step-up dosing, patient monitoring, interdisciplinary communication, and coordination of care.
4. Identify the roles of the oncology multidisciplinary team in supporting safe medication-use processes, treatment coordination, and patient education for emerging multiple myeloma therapies.
5. Summarize practical approaches to optimizing patient outcomes through multidisciplinary management of patients receiving CAR T-cell therapy, bispecific antibodies, and novel CELMoD therapies.



From Implementation to Impact: Lessons from the NCODA BTCE Mentorship Program

CE Accreditation: Pharmacists, Pharmacy Technicians, Physicians, Nurses, Nurse Practitioners, Physician Assistants

Date of Activity: October 29, 2026

LecturePanda Exp Date: December 28, 2026

SESSION DESCRIPTION

Hear directly from mentors and mentees as they reflect on their experiences implementing bispecific T-cell engager (BTCE) therapies through the NCODA Mentorship Program. This panel discussion will share practical lessons learned, successful strategies, ongoing challenges, and perspectives on implementing BTCE programs across a variety of practice settings. Participants will explore multidisciplinary roles, staff training, toxicity management, REMS processes, and care coordination, including transitions of care. The discussion will highlight approaches to overcoming implementation barriers and adapting workflows to institutional resources and patient needs.

LEARNING OBJECTIVES

1. Describe the roles, workflows, and resources needed to support bispecific T-cell engager (BTCE) therapy implementation in oncology practice.
2. Explain approaches for staff training, toxicity management, REMS processes, care coordination, and transitions of care during BTCE therapy implementation.
3. Discuss strategies to combat barriers to BTCE therapy implementation in oncology practice.

Advancing Care in Low-Grade Serous Ovarian Cancer: Integrating Molecular Testing into Clinical Decision Making

CE Approval: Pharmacists, Pharmacy Technicians, Physicians, Nurses, Nurse Practitioners, Physician Assistants

Date of Activity: October 29, 2026

LecturePanda Exp Date: December 28, 2026

SESSION DESCRIPTION

Low-grade serous ovarian cancer (LGSOC) is a distinct histologic subtype with unique molecular and biological characteristics that inform its treatment approach. This presentation will compare these characteristics with those of other ovarian cancer subtypes and review recommended molecular testing approaches and biomarkers relevant to LGSOC. Participants will explore current and emerging treatment strategies, including biomarker-directed options. Patient-case examples will provide opportunities to interpret molecular testing results and use molecular and clinical factors to guide treatment selection and clinical decision-making.

LEARNING OBJECTIVES:

1. Describe the molecular and biological characteristics of low-grade serous ovarian cancer (LGSOC), including key differences from other ovarian cancer subtypes.

2. Identify recommended molecular testing approaches in ovarian cancer, including biomarkers relevant to LGSOC.
 3. Discuss current and emerging treatment strategies for patients with LGSOC based on molecular and clinical factors.
 4. Interpret molecular testing results from patient-case examples to guide treatment selection and clinical decision-making in LGSOC.
-



AI Unfiltered: A Live PQI Podcast on the Future of Oncology

CE Approval: Pharmacists, Pharmacy Technicians, Physicians, Nurses, Nurse Practitioners, Physician Assistants

Date of Activity: October 30, 2026

LecturePanda Exp Date: December 29, 2026

SESSION DESCRIPTION

This live PQI Podcast session will demystify artificial intelligence (AI) by defining foundational terms, briefly tracing its evolution, and explaining why recent advances have accelerated its visibility and adoption. The discussion will examine AI's benefits, limitations, and safety considerations, including bias, privacy, transparency, accuracy, and appropriate human oversight. Participants will explore current and emerging applications in routine oncology care, including diagnosis, patient education, and communication, as well as clinical research applications such as trial matching, study design, data analysis, and drug development. Practical examples available to oncology teams today will be distinguished from emerging applications that may shape cancer care in the future.

LEARNING OBJECTIVES:

1. Define foundational AI concepts including machine learning, generative AI, and large language models.
 2. Describe key benefits, limitations, and safety considerations associated with the use of AI in healthcare and oncology.
 3. Identify current and emerging applications of AI in routine oncology care, including diagnosis and patient education and communication.
 4. Explain how AI is being applied to oncology clinical research and clinical trials.
-



Fixed Duration, Forward Thinking: Evolving CLL Treatment

CE Approval: Pharmacists, Pharmacy Technicians, Physicians, Nurses, Nurse Practitioners, Physician Assistants

Date of Activity: October 29, 2026

LecturePanda Exp Date: December 28, 2026

SESSION DESCRIPTION

This activity will review the clinical evidence, safety profiles, and practical considerations for fixed-duration treatment approaches in chronic lymphocytic leukemia (CLL). Case-based examples will explore how disease characteristics, comorbidities, patient preferences, and logistical considerations influence treatment selection. Discussion will also address monitoring, toxicity management, and interdisciplinary care to support safe implementation.

LEARNING OBJECTIVES: PHARMACISTS, NURSES, NURSE PRACTITIONERS, PHYSICIANS, & PHYSICIAN ASSISTANTS

1. Discuss the key clinical evidence, safety profiles, and practical considerations associated with fixed-duration treatment approaches in chronic lymphocytic leukemia (CLL).
2. Apply patient- and disease-specific factors that influence the selection of fixed-duration therapy in CLL through case-based examples.

LEARNING OBJECTIVES: PHARMACY TECHNICIANS

1. Discuss the key clinical evidence, safety profiles, and practical considerations associated with fixed-duration treatment approaches in chronic lymphocytic leukemia (CLL).
2. Identify patient-specific factors that warrant pharmacist review when supporting fixed-duration therapy in CLL through case-based examples.



Protecting Future Possibilities: Integrating Fertility Preservation Across the Cancer Care Continuum

CE Approval: Pharmacists, Pharmacy Technicians, Physicians, Nurses, Nurse Practitioners, Physician Assistants

Date of Activity: October 29, 2026

LecturePanda Exp Date: December 28, 2026

SESSION DESCRIPTION

This activity will help oncology professionals identify patients at risk for treatment-related infertility and integrate fertility preservation into comprehensive cancer care. Participants will explore established and emerging preservation options, including the appropriate role and limitations of GnRH agonists, and opportunities for counseling and referral before, during, and after treatment. The session will emphasize multidisciplinary communication, shared decision-making, and strategies to address misconceptions and barriers to care. Particular attention will be given to pediatric and adolescent and young adult patients, with reproductive health and future family-building considerations addressed from diagnosis through survivorship.

LEARNING OBJECTIVES:

1. Discuss treatment-related infertility risks, fertility preservation options, and reproductive health considerations for pediatric, adolescent and young adult, and adult patients within multidisciplinary oncology care.
2. Apply patient-centered communication and shared decision-making strategies regarding fertility preservation counseling, referral, and ongoing reproductive health needs in patient case scenarios across the cancer care continuum.



The Next Frontier: Emerging Career Pathways for Oncology Pharmacy Technicians

CE Approval: Pharmacists, Pharmacy Technicians

Date of Activity: October 29, 2026

LecturePanda Exp Date: December 28, 2026

SESSION DESCRIPTION

Oncology pharmacy technicians are assuming increasingly specialized roles that extend beyond traditional responsibilities and support evolving models of oncology care. This knowledge-based session will explore emerging career pathways through real-world practice examples and discussion of the competencies, experiences, and professional development strategies that support these roles. Participants will gain insight into how technician responsibilities are evolving across oncology practice settings and identify opportunities to strengthen technician contributions to patient care, operational excellence, and professional growth.

LEARNING OBJECTIVES:

1. Describe emerging and evolving career pathways available to oncology pharmacy technicians and their contributions to contemporary oncology practice.
 2. Identify the transferable knowledge, skills, and competencies associated with expanded oncology pharmacy technician roles across diverse practice settings.
 3. Discuss professional experiences, challenges, and development strategies, including mentorship and lifelong learning, that support professional growth in specialized oncology pharmacy technician roles.
 4. Describe how optimizing the technician role and expanding responsibilities contribute to operational excellence, interdisciplinary collaboration, and high-quality, patient-centered oncology care.
-

The New Access Landscape: Preparing Oncology Practices for Coverage Changes in 2027

CE Approval: Pharmacists, Pharmacy Technicians, Physicians, Nurses, Nurse Practitioners, Physician Assistants

Date of Activity: October 29, 2026

LecturePanda Exp Date: December 28, 2026

SESSION DESCRIPTION

This activity will examine federal healthcare policy changes affecting insurance eligibility, enrollment, and access to care as oncology practices prepare for 2027. The session will focus on Medicaid and Affordable Care Act Marketplace requirements associated with the One Big Beautiful Bill Act (OBBBA) and the Marketplace Integrity and Affordability Final Rule, with a brief review of relevant Medicare implications. Participants will explore potential effects on insurance coverage, treatment access, and financial burden for patients with chronic medical conditions. The discussion will address preparation strategies and practical considerations for oncology teams supporting patients through coverage changes.

LEARNING OBJECTIVES:

1. Describe the pending enrollment criteria and barriers to enrollment in Medicaid as well as the Marketplace set in place by the One Big Beautiful Bill Act (OBBBA) and the Marketplace Integrity and Affordability Final Rule.
2. Discuss how the new enrollment criteria and barriers for Medicaid as well as the Marketplace may impact insurance coverage, treatment access, and financial burden for patients with chronic medical conditions.
3. Identify preparation strategies for oncology care teams as they prepare for the potential impact of these policy changes on their patient populations.



From Prescription to Persistence: Optimizing Access & Adherence Across the OAM Journey

CE Approval: Pharmacists, Pharmacy Technicians, Physicians, Nurses, Nurse Practitioners, Physician Assistants

Date of Activity: October 29, 2026

LecturePanda Exp Date: December 28, 2026

SESSION DESCRIPTION

Participants will use the NCODA/ONS Oral Anticancer Medication (OAM) Care Compass to explore strategies for addressing barriers across the OAM journey, including access, education, adherence, toxicity management, documentation, and persistence. Through perspectives from the Oncology Nursing Society, an established OAM nurse navigator program, and a practice without a formal OAM program, attendees will examine workflow ownership and approaches to closing care gaps. Learners will then apply the Care Compass in a team-based activity to identify barriers, assign ownership, develop workflow interventions, and define measures of success. Participants will leave with practical strategies to strengthen OAM processes and support patient-centered outcomes.

LEARNING OBJECTIVES:

1. Describe how the NCODA/ONS Oral Anticancer Medication (OAM) Care Compass may be used to address barriers to care.
2. Examine the role of workflow ownership in a formal OAM program to reduce gaps in care.
3. Compare approaches used by formal versus informal OAM programs to address barriers across the patient journey.
4. Demonstrate application of available resources to address workflow gaps within individual practice settings through group activity.



Thinking Beyond the Task: Strengthening Clinical Judgment & Accountability in Oncology Nursing

CE Approval: Pharmacists, Pharmacy Technicians, Physicians, Nurses, Nurse Practitioners, Physician Assistants

Date of Activity: October 29, 2026

LecturePanda Exp Date: December 28, 2026

SESSION DESCRIPTION

This session explores clinical judgment and professional accountability in oncology nursing through Tanner's Clinical Judgment Model and Benner's novice-to-expert framework. Infusion-related reaction and triage/telephone symptom management scenarios will illustrate how clinicians recognize evolving concerns and determine appropriate responses. Through a case-based lecture and small-group activity, participants will examine how safety culture, near-miss/miss reporting, systems-level factors, and differing experience levels influence clinical judgment. The session will also explore how accountability and emotional intelligence support appropriate clinical responses and communication within the multidisciplinary oncology team.

LEARNING OBJECTIVES:

1. Describe how Tanner's Clinical Judgment Model (noticing, interpreting, responding, reflecting) applies to evolving clinical concerns, including infusion-related reactions and triage/telephone symptom management in a variety of oncology settings.
2. Discuss how culture of safety, near-miss/miss reporting, and systems-level factors support or constrain clinical judgment at the point of care.
3. Explain how clinicians across Benner's novice-to-expert continuum contribute differently, with advanced beginners bringing transferable safety knowledge from prior settings to inform systems and protocols, and experts bringing pattern recognition to the bedside.
4. Outline how principles of accountability and emotional intelligence inform an appropriate clinical response in a case-based infusion scenario.



2026 NCODA Fall Summit CE Poster Presentations

CE Approval: Pharmacists, Pharmacy Technicians, Physicians, Nurses, Nurse Practitioners, Physician Assistants

Date of Activity: October 29, 2026

Time: 5:15–6:15 PM Eastern

LecturePanda Exp Date: December 28, 2026

SESSION DESCRIPTION

This poster session will highlight emerging research findings, practice trends, and improvement initiatives relevant to oncology care. Participants will review posters and engage with presenters to explore strategies supporting patient care, medication safety, and operational efficiency. The session will emphasize multidisciplinary collaboration and evidence-based approaches to advancing oncology practice.

LEARNING OBJECTIVES:

1. Identify emerging research findings and practice trends relevant to oncology care.
2. Describe strategies to improve patient care, medication safety, and operational efficiency in oncology practice.
3. Recognize the role of multidisciplinary collaboration and evidence-based approaches in advancing oncology care.